CCL22 and hematologic disorder: Through the release of CCL22/CCR4 and PGE2 or H-ferritin, tumor cells, including those in hematologic malignancies, cause attraction and expansion of Treg cells to the tumor site and in peripheral blood (PB), thereby increasing Treg cells in the tumor microenvironment and in PB [37].